FULC

Fulcrum Therapeutics (FULC)

About Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Details

Daily high

$10.00

Daily low

$9.62

Price at open

$9.71

52 Week High

$15.74

52 Week Low

$2.32

Market cap

630.0M

Dividend yield

0.00%

Volume

489,219

Avg. volume

696,787

P/E ratio

-8.10

Fulcrum Therapeutics News